Neurizon Therapeutics Limited a annoncé que la Food and Drug Administration (FDA) des États-Unis a levé la suspension clinique de son principal médicament expérimental, le NUZ-001. Cette décision ...
MELBOURNE, Australia, Oct. 6, 2025 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative ...
NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease Treatment prevented hallmark developmental and ...
Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to advise that results from an independent ...
06/10 La FDA lève la suspension clinique sur le NUZ-001 RE 06/10 La FDA américaine lève la suspension clinique sur le NUZ-001 de Neurizon Therapeutics RE 06/10 La FDA lève la suspension clinique sur ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback